Recombinant human neuregulin-1beta on survival in chronic systolic heart failure
Chronic Heart Failure
Enrolment: 679 · Results not recorded
Loading the evidence…
Biologic · Cell therapy with an adenoviral NRG1 transgene; no ChEMBL entity. FLAGGED: to_trial=true rests on recombinant NRG1 PROTEIN delivery (Neucardin rhNRG-1, Zensun; GGF2/cimaglermin, Acorda), not on NRG1-transduced MSCs - payload-level evidence with a different modality, needs manual review. Seribantumab (anti-HER3) and NRG1-genotype schizophrenia studies were excluded as opposite-direction or not NRG1 interventions.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Chronic Heart Failure
Enrolment: 679 · Results not recorded
Chronic Heart Failure
Enrolment: 67 · Results not recorded
Heart Failure
Enrolment: 40 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Transient focal cerebral ischaemia by intraluminal silicone-coated filament occlusion of the left middle cerebral artery for 60 min followed by reperfusion
NRG1-AdMSCs lowered modified Neurological Severity Scores and reduced infarct volume at 14 days compared with PBS, adenoviral NRG1 and naive AdMSCs, with higher exogenous and endogenous NRG1 and raised ErbB4, pMAPK and pAkt in the ischaemic hemisphere.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.